Medifocus, Inc. Announces Global Market Expansion with Prolieve® Performed and Reimbursed by Insurance Carriers in Hong Kong COLUMBIA, Md. and TORONTO, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Medifocus, Inc. (OTCQB:…
Medifocus, Inc. Announces Recent Publication Highlighting Its Focal Therapy for Prostate and Breast Cancer Treatment Initiatives COLUMBIA, Md. and TORONTO, Dec. 27, 2018 (GLOBE NEWSWIRE) -- Medifocus, Inc. (OTCQB: MDFZF…
Medifocus, Inc. Announces FDA PMA Supplement Approval for New Labeling Based on Successful Completion of FDA Post Approval Study (PAS) for the Prolieve® Thermodilatation™ Device COLUMBIA, Md. and TORONTO, Dec.…
Medifocus, Inc. Submits For New Patent Titled “Thermodilatation and Thermocompression to Facilitate Targeted Cluster Tissue Ablation and Immune Response” COLUMBIA, MD and TORONTO, ON / ACCESSWIRE / November 29, 2018…
Medifocus, Inc. Announces 26% Increase in Revenue in Recent Quarter and Positive Cash Flow from Operation for the Six Months Ended Sept 30, 2018 COLUMBIA, MD and TORONTO, ON /…